Generic Name and Formulations:
Bupivacaine 13.3mg/mL; liposome injectable suspension; preservative-free.
Pacira Pharmaceuticals, Inc.
Indications for EXPAREL:
For infiltration to produce postsurgical local analgesia. As interscalene brachial plexus nerve block to produce postsurgical regional analgesia.
For single-dose administration only. Inject slowly (usually 1–2mL per inj); perform frequent aspiration to check for blood. Local infiltration (base dose on surgical site and volume required to cover area): up to max 266mg (20mL); (bunionectomy): 106mg (8mL); (hemorrhoidectomy): 266mg (20mL). Regional nerve block: max 133mg (10mL). See full labeling for administration.
<18yrs: not recommended.
Obstetrical paracervical block.
Not interchangeable with other forms of bupivacaine. Avoid intravascular, intra-articular, intrathecal, epidural, or other regional nerve blocks. To be administered under the supervision of experienced clinicians. Cardiovascular disease. Potential temporary sensory and/or motor loss lasting up to 5 days. Renal or moderate-to-severe hepatic impairment (monitor for toxicity). Monitor neurologic, cardiovascular and respiratory vital signs. Elderly. Pregnancy. Nursing mothers.
Local anesthetic (amide-type).
Do not dilute with water or hypotonic agents (may result in disruption of liposomal particles). Do not mix with lidocaine or other non-bupivacaine-based local anesthetics. Avoid additional local anesthetics within 96hrs following administration of Exparel. May administer after at least 20 mins following local administration of lidocaine. Bupivacaine HCl, when injected immediately before or admixed with Exparel, may impact the pharmacokinetic and/or physicochemical properties of the drugs; may be admixed simultaneously or inject bupivacaine HCl immediately before Exparel as long as the mg dose ratio of bupivacaine HCl to Exparel does not exceed 1:2. Avoid contact with antiseptics (eg, povidone iodine).
Nausea, constipation, vomiting, pyrexia; CNS effects (eg, excitation, depression, restlessness, anxiety, dizziness, tinnitus, blurred vision, tremors), cardiovascular effects (eg, decreased cardiac output, AV block, ventricular arrhythmias, cardiac arrest), allergic-type reactions, neurologic effects (eg, paresthesia, weakness, paralysis), chondrolysis.
Single-use vial (10mL, 20mL)—4, 10
Clinical Pain Advisor Articles
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis